Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-12-24

Clinical Trial Update: A Long Term Safety Study of Degarelix in Patients With Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety study of degarelix in patients with prostate cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Firmagon (Degarelix)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2012-12-24